https://www.oncnursingnews.com/view/fda-accepts-new-drug-application-to-darolutamide-plus-adp-for-mhspc
FDA Accepts New Drug Application to Darolutamide Plus ADP for mHSPC | Oncology Nursing News
Oct 10, 2026 - The FDA accepted a supplemental new drug application to darolutamide plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer.
new drug applicationoncology nursingfdaacceptsdarolutamide
https://www.gustaveroussy.fr/presse/avancees-cliniques-scientifiques/nejm-darolutamide-augmente-survie-patients-atteints-dun
NEJM : le darolutamide augmente la survie des patients atteints d’un cancer de la prostate |...
Sep 10, 2020 - Villejuif, le 10 septembre 2020 New England Journal of Medicine Le darolutamide augmente la survie des patients atteints d’un cancer de la prostate Les…
nejmdarolutamideaugmentesurviedes
https://connect.mayoclinic.org/discussion/anyone-taking-nubeqa-have-a-problem-with-constipation/
Anyone taking Nubeqa (darolutamide) have a problem with constipation? | Mayo Clinic Connect
I just started getting constipated; I'm on nubeqa. Has anyone here on nubeqa that has gotten constipated.Thanks
problem withmayo clinicanyonetakingnubeqa